EUCTR2008-001769-27-GB进行中(未招募)不适用
Microbiological assessment of prophylactic ciprofloxacin therapy for children with cystic fibrosis during viral respiratory viral infection to prevent Pseudomonas aeruginosa colonisation – a randomised control study (Prevent Pseudomonas Aeruginosa Colonisation- PREPAC) - PREPAC
Southampton University Hospital Trust0 个研究点目标入组 45 人开始时间: 2008年10月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Confirmed diagnosis of Cystic Fibrosis and attending the regional CF service for care exclusively at Southampton or at both Southampton and Poole General Hospitals.
- •2. Aged 2-14 years
- •3. Negative ELISA serology for P. aeruginosa at study entry.
- •4. Not chronically infected with pseudomonas aeruginosa.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Positive pseudomonas serology on ELISA testing
- •2.Any other evidence suggesting chronic P. aeruginosa infection
- •3.Chronic infection with any other gram negative CF pathogen
- •4.Past history of allergic reaction or any other significant adverse reaction to previous treatment with oral ciprofloxacin.
- •5.Ongoing participation any other clinical trial at time of study entry.
- •6.Parents or guardians unwilling to give informed consent for study inclusion.
- •7.Patients who have a recognised indication for other antibiotics
- •8.Immunosuppressive/immunomodulatory therapy
- •9.Significant immunocompromise (eg HIV infection)
- •10.Advanced malignancy
- •12.Children not likely to survive the time period of the intervention
- •13.Patients who have undergone organ transplantation (including bone marrow transplantation)
- •14.Patients undergoing plasma exchange or whole blood exchange transfusion
- •15.Treatment with an investigational drug or device within the last 30 days prior to enrolment.
- •16.Immediate families of investigators or site personnel directly affiliated with the study. Immediate family is defined as child or sibling, whether biological or legally adopted.
研究者
相似试验
尚未招募
Unknown
Study On Antimicrobial Prophylaxis And Incidence Of Surgical Site InfectioCTRI/2024/07/071422I
进行中(未招募)
不适用
Prulifloxacin in ABRSMale or female adults with ABRS, defined as the presence of 2 (including at least one between nasal blockage/congestion/ obstruction or nasal discharge) or more of the following signs and symptoms: nasal blockage/congestion/obstructionnasal discharge (anterior/post nasal drip)facial pain/pressurereduction/loss of smell. Persistent symptoms for 10 days or an increase of symptoms after 5 days, and with a duration lower then 12 weeks.EUCTR2011-002955-33-ROAziende Chimiche Riunite Angelini Francesco S.p.A
已完成
不适用
Evaluation of efficacy of prophylactic antibiotic therapy in prevention of incidence of meningitis in patient with basilar skull fracture and cerebrospinal fluid leakageFracture of base of skull due to trauma.Fracture of base of skullIRCT2014123020485N1Ahvaz Jundishapour Medical University346
已完成
不适用
Short-term administration of prulifoxacin: a preventive strategy to reduce Bacillus Calmette-Guerin (BCG)-induced toxicity in patients with superficial bladder cancerCancerISRCTN90497703Magna Graecia University of Catanzaro (UMG) (Italy)70
已完成
不适用
To study ciprofloxacin pharmacokinetics in patients who are critically ill and undergoing continuous dialysisPatients on dialysisNutritional, Metabolic, EndocrineRenal failureISRCTN52722850Trinity College Dublin (Ireland)7
